Janssen’s RSV vaccine provides 80 percent protection in Phase II study
Posted: 4 October 2021 | Anna Begley (European Pharmaceutical Review) | No comments yet
The investigational respiratory syncytial virus (RSV) vaccine candidate demonstrated 80 percent efficacy in adults aged 65 and older.
Janssen has announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent in adults aged 65 and older the Phase IIb study, CYPRESS (NCT03982199).
The trial enrolled 5,782 participants – 2,891 in each study arm – aged 65 years and older. The participants were randomised 1:1 prior to the RSV season to receive Janssen’s investigational adult vaccine or placebo. Immunogenicity and safety assessments were performed in a subset of approximately 200 and 695 participants, respectively. Disease symptoms were collected through a questionnaire and/or by a clinician’s assessment.
The primary endpoint was the first occurrence of reverse transcription polymerase chain reaction (RT-PCR) confirmed LRTD caused by RSV according to any of three case definitions: three or more symptoms of lower respiratory tract infection (LRTI); two or more symptoms of LRTI; or two or more symptoms of LRTI or one or more symptom of LRTI with one or more systemic symptom. The secondary efficacy endpoint was the first occurrence of any RT–PCR-confirmed RSV-associated acute respiratory infection (ARI).
The CYPRESS study met its primary and secondary endpoints, with the investigational adult vaccine demonstrating efficacy of 80 percent against confirmed RSV-associated LRTD. The vaccine also demonstrated efficacy of 70 percent against any symptomatic RSV-associated ARI.
The vaccine candidate also elicited robust humoral and cellular immune responses in adults aged 65 and older, with participants in the immunogenicity subset showing a substantial increase in RSV neutralising antibodies 14 days after vaccination. The vaccine was generally well-tolerated in all vaccinated participants.
Based on the positive results from the Phase IIb CYPRESS study, which is the first large study evaluating the efficacy and safety of Janssen’s investigational RSV vaccine against RSV-associated LRTD in adults aged 65 and older in the US, Janssen initiated the global Phase II EVERGREEN study. The Phase III study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against LRTD caused by RSV, when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.
Big Pharma, Clinical Trials, Data Analysis, Drug Safety, Immunisation, Research & Development (R&D), Vaccines, Viruses
Related diseases & conditions
respiratory syncytial virus (RSV)-mediated lower respiratory tract disease